Legend Capital

Legend Capital is a Beijing-based venture firm with a long-running healthcare practice spanning biotech, medical devices, and pharma and therapeutics. The firm has been one of the more visible Chinese venture investors over many cycles and brings a track record of building companies from earlier rounds through to maturity. Legend Capital’s healthcare positioning combines scientific and clinical depth with the operational experience of having seen many Chinese healthcare companies through the regulatory, commercial, and capital markets transitions that define the sector. Limited public information is available about specific named partners attributed to individual deals in this profile, though the firm’s institutional standing is widely recognized.

Check sizes typically run from ten to thirty million dollars, deployed across Series A, Series B, and Series C rounds. Geographic focus is centered on China, with selective cross-border activity where opportunities align. The stage range positions Legend Capital as a meaningful initial venture investor in some rounds and a continuing growth participant in others, depending on opportunity dynamics.

For founders, Legend Capital is a natural conversation for Chinese healthcare companies that want a sector-experienced venture firm rather than a pure financial investor. Expect engagement on scientific and clinical risk, regulatory strategy, and the practical realities of building a healthcare business in China. Founders with little China connection or whose strategy is purely Western-focused will likely find a less natural fit. The strongest match is a serious biotech, device, or pharma company at Series A through Series C, where Legend Capital’s experience across many prior portfolio companies translates into meaningful operating support.